Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Burisch

Showing results (21-30 of 272) with videos related to

Pageof 28
Sort By:
Gut|March 4, 2021
Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?Mohamed Attauabi, Jakob Seidelin, Johan Burisch, et al.
Alimentary Pharmacology & Therapeutics|April 16, 2022
Letter: the clinical course of Crohn's disease-the Sicilian experience. Authors' replyJohan Burisch, Ebbe Langholz, Pia Munkholm
Danish Medical Journal|March 31, 2023
Identifying patients with inflammatory bowel disease in the Danish National Patient RegisterBobby Lo, Mirabella Zhao, Johan Burisch
Revista Espanola De Enfermedades Digestivas|July 21, 2017
The complexity of evaluating and increasing adherence in inflammatory bowel diseasePetra Weimers, Johan Burisch, Pia Munkholm
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 3, 2019
Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in DenmarkJohan Burisch, Tine Jess, Alexander Egeberg
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 4, 2022
Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis"Mohamed Attauabi, Jakob Benedict Seidelin, Johan Burisch
Journal of Crohn'S & Colitis|November 20, 2020
Authors' Reply to: 'COVID-19 in the IBD Population: The Need for Correct Nomenclature'Mohamed Attauabi, Jakob Benedict Seidelin, Johan Burisch
Current Opinion in Clinical Nutrition and Metabolic Care|August 3, 2017
Whats 'App-ening': the help of new technologies in nutrition in digestive diseasesDorit V Ankersen, Petra Weimers, Johan Burisch
Inflammatory Bowel Diseases|November 17, 2020
Efficacy of Ustekinumab for Active Perianal Fistulizing Crohn Disease: A Double-Center Cohort StudyMohamed Attauabi, Johan Burisch, Jakob Benedict Seidelin
Scandinavian Journal of Gastroenterology|December 2, 2020
Efficacy of ustekinumab for active perianal fistulizing Crohn's disease: a systematic review and meta-analysis of the current literatureMohamed Attauabi, Johan Burisch, Jakob Benedict Seidelin
Pageof 28

Showing results (21-30 of 272) with videos related to

Sort By:
Pageof 28
Gut|March 4, 2021
Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?Mohamed Attauabi, Jakob Seidelin, Johan Burisch, et al.
Alimentary Pharmacology & Therapeutics|April 16, 2022
Letter: the clinical course of Crohn's disease-the Sicilian experience. Authors' replyJohan Burisch, Ebbe Langholz, Pia Munkholm
Danish Medical Journal|March 31, 2023
Identifying patients with inflammatory bowel disease in the Danish National Patient RegisterBobby Lo, Mirabella Zhao, Johan Burisch
Revista Espanola De Enfermedades Digestivas|July 21, 2017
The complexity of evaluating and increasing adherence in inflammatory bowel diseasePetra Weimers, Johan Burisch, Pia Munkholm
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 3, 2019
Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in DenmarkJohan Burisch, Tine Jess, Alexander Egeberg
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 4, 2022
Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis"Mohamed Attauabi, Jakob Benedict Seidelin, Johan Burisch
Journal of Crohn'S & Colitis|November 20, 2020
Authors' Reply to: 'COVID-19 in the IBD Population: The Need for Correct Nomenclature'Mohamed Attauabi, Jakob Benedict Seidelin, Johan Burisch
Current Opinion in Clinical Nutrition and Metabolic Care|August 3, 2017
Whats 'App-ening': the help of new technologies in nutrition in digestive diseasesDorit V Ankersen, Petra Weimers, Johan Burisch
Inflammatory Bowel Diseases|November 17, 2020
Efficacy of Ustekinumab for Active Perianal Fistulizing Crohn Disease: A Double-Center Cohort StudyMohamed Attauabi, Johan Burisch, Jakob Benedict Seidelin
Scandinavian Journal of Gastroenterology|December 2, 2020
Efficacy of ustekinumab for active perianal fistulizing Crohn's disease: a systematic review and meta-analysis of the current literatureMohamed Attauabi, Johan Burisch, Jakob Benedict Seidelin
Pageof 28